HM
HMTXF.US Hemostemix Inc
- Market cap
- USD 7.40M
- P/E
- -
- P/B
- 39.23x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is HMTXF.US undervalued?
Graham numberThe Graham number of Hemostemix Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hemostemix Inc fundamental analysis
No fundamental analysis for Hemostemix Inc yet.
Hemostemix Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hemostemix Inc
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which completed Phase II clinical trial for the treatment of peripheral arterial disease, chronic limb threatening ischemia, cardiovascular ischemia and angina, and vascular dementia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain…
Full company profileHemostemix Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hemostemix Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -1.69K | -2.45K | -1.10K | -495.00 | -223.00 | - | - | - |
| Operating Income | -3.71M | -2.81M | -6.42M | -4.70M | -7.47M | -6.67M | -4.58M | -2.33M | -1.98M | -5.63M | -2.73M |
| EBITDA | -3.67M | -2.81M | -6.64M | -4.69M | -7.47M | -2.77M | -4.58M | -2.33M | -2.00M | -4.26M | -2.60M |
| Net Income | -3.78M | -3.93M | -6.19M | -4.87M | -7.77M | -6.29M | -5.24M | -2.50M | -2.62M | -4.71M | -2.84M |
| EPS | -1.12 | -0.56 | -0.41 | -0.32 | -0.24 | -0.11 | -0.07 | -0.03 | -0.02 | -0.02 | -0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 227K | 5.30M | 1.66M | 104K | 2.32M | 563K | 465K | 314K | 992K | 847K | 257K |
| Total Liabilities | 3.69M | 465K | 1.17M | 4.15M | 3.42M | 5.85M | 7.23M | 7.68M | 8.20M | 5.82M | 6.02M |
| Shareholders' Equity | -3.46M | 4.84M | 488K | -4.05M | -1.10M | -5.28M | -6.77M | -7.37M | -7.20M | -4.97M | -5.76M |
| Cash & Short-term Investments | 34.8K | 5.21M | 1.47M | 24.1K | 258K | 219K | 136K | 155K | 706K | 682K | 139K |
| Total Debt | 1.39M | - | - | 2.06M | 175K | 1.48M | 4.13M | 4.32M | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.69M | -3.21M | -2.69M | -3.40M | -5.98M | -3.48M | -6.10M | -1.42M | -1.90M | -4.53M | -2.39M |
| Capital Expenditure | 1.53K | 6.14K | 6.14K | 6.14K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -2.69M | -3.21M | -2.69M | -3.41M | -5.98M | -3.48M | -6.10M | -1.42M | -1.90M | -4.53M | -2.39M |
| Ratios | |||||||||||
| ROE | - | -81.3% | -1,268.5% | - | - | - | - | - | - | - | - |
| ROA | -1,666.4% | -74.2% | -372.2% | -4,669.9% | -334.4% | -1,116.4% | -1,125.1% | -797.4% | -263.8% | -556.6% | -1,106.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Hemostemix Inc dividends
Hemostemix Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:20 on Dec 30, 2020.
Who owns Hemostemix Inc
- Insiders 16.05%
- Institutions 0.00%
- Public & others 83.95%
- Shares outstanding 211M
- Free float 168M
Hemostemix Inc company profile
- Company name
- Hemostemix Inc
- Ticker
- HMTXF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 707-7th Avenue SW, Calgary, AB, Canada, T2P 3H6
- Phone
- 905-580-4170
- Website
- hemostemix.com
About Hemostemix Inc
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which completed Phase II clinical trial for the treatment of peripheral arterial disease, chronic limb threatening ischemia, cardiovascular ischemia and angina, and vascular dementia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Hemostemix Inc management
4- Mr. Thomas A. Smeenk B.A., BA HonsCo-Founder, President, CEO & Director · born 1962
- Ms. Christina Wu CPAInterim Chief Financial Officer
- Mr. Peter PavlinVice President of Operations
- Dr. Fraser C. Henderson Sr., M.D.Chief Medical Officer